Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.…
Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology Platform
Cingulate (NASDAQ: CING) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 4.510 USD on 20 November 2026, up 20.9% over 52 weeks. Its 52-week range is 3.160 USD to 11.89 USD: the price is 62.1% below the high and 42.7% above the low.
Its market capitalisation is 67.48M USD.
Cingulate reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 22.11M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.